基于粪便免疫化学检测的结直肠癌筛查项目的长期性能
该研究在50至69岁人群中重复进行粪便免疫化学检测(FIT)筛查,评估每轮筛查的阳性率、结直肠癌和进展期腺瘤检出率及阳性预测值,并计算五轮FIT后的累积检出率。结果显示重复FIT可显著降低结直肠疾病负担,五轮FIT后的累积检出率与结肠镜初筛相似。
要点
- 结直肠癌和进展期腺瘤检出率从第一轮到第三轮(RR 0.25,95%CI 0.20至0.32)和第二轮(RR 0.51,95%CI 0.47至0.56)大幅下降后趋于稳定。
- 进展期肿瘤的阳性预测值在第二轮下降18%(RR 0.82,95%CI 0.77至0.89),此后因FIT阳性率同步下降而无进一步降低。
- 连续五轮FIT的累积结直肠癌检出率为8.5‰(95%CI 7.8至9.2),累积进展期腺瘤检出率为58.9‰(95%CI 56.9至61.0)。
核心结论
- 重复FIT显著减少结直肠疾病负担,同时促进结肠镜资源的有效利用。
- 五轮FIT后的累积检出率与结肠镜初筛相似,支持在评估FIT效力时考虑重复FIT的累积敏感性。
研究设计与样本
- 研究纳入50至69岁人群,重复接受FIT筛查(OC-Hemodia乳胶凝集试验;截断值:20微克血红蛋白/克粪便)。
- 在12年(2002-2014年)间,123 347名个体接受了最多六次FIT检测。
主要发现
- 共诊断781例结直肠癌和4713例进展期腺瘤。
- 结直肠癌检出率从第一轮到第三轮下降(RR 0.25,95%CI 0.20至0.32),进展期腺瘤检出率从第一轮到第二轮下降(RR 0.51,95%CI 0.47至0.56),之后均保持稳定。
- 进展期肿瘤的阳性预测值在第二轮下降18%(RR 0.82,95%CI 0.77至0.89),此后无进一步下降,归因于FIT阳性率同步下降(第一轮至第六轮RR 0.56,95%CI 0.53至0.60)。
- 连续五轮FIT的累积结直肠癌检出率为8.5‰(95%CI 7.8至9.2),累积进展期腺瘤检出率为58.9‰(95%CI 56.9至61.0)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The long-term performance of colorectal cancer (CRC) screening programmes based on a 2-year faecal immunochemical test (FIT) is still unclear. METHODS: In a sample of 50 to 69-year-olds repeatedly screened with the FIT (OC-Hemodia latex agglutination test; cut-off: 20 µg haemoglobin/g faeces), we examined: (1) the FIT positivity rate, the CRC and advanced adenoma detection rate and the FIT's positive predictive value (PPV) for advanced neoplasia, at each round of screening and (2) the cumulative CRC and advanced adenoma detection rate after five rounds of FIT. RESULTS: Over 12 years (2002-2014), 123 347 individuals were administered the FIT up to six times, and 781 CRCs and 4713 advanced adenomas were diagnosed. The CRC and advanced adenoma detection rates declined substantially from the first to the third (rate ratio (RR) 0.25, 95% CI 0.20 to 0.32) and second (RR 0.51, 95% CI 0.47 to 0.56) rounds, respectively, and then remained stable. The PPV for advanced neoplasia dropped by 18% in the second round (RR 0.82, 95% CI 0.77 to 0.89), with no further reduction thereafter due to a concomitant decline in the FIT positivity rate (RR first to sixth rounds: 0.56, 95% CI 0.53 to 0.60).The cumulative CRC and advanced adenoma detection rates over five consecutive rounds were 8.5‰ (95% CI 7.8 to 9.2), and 58.9‰ (95% CI 56.9 to 61.0), respectively. CONCLUSIONS: Repeated FIT significantly reduces the burden of colorectal disease while facilitating an efficient use of colonoscopy resources. The cumulative detection rate after five rounds of FIT is similar to primary screening with colonoscopy, supporting the need to account for the cumulative sensitivity of repeated FITs when evaluating the test's efficacy.
引用
- Zorzi M, Hassan C, Capodaglio G, et al. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test. Gut. 2017. PMID: 29101260. doi:10.1136/gutjnl-2017-314753
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。